Evidence map›Paper›PMID 35199839›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022

The Role of TRP Channels in Nicotinic Provoked Pain and Irritation from the Oral Cavity and Throat: Translating Animal Data to Humans.

Lars Arendt-Nielsen, Earl Carstens, Gordon Proctor, Yves Boucher, Pere Clavé, Kent Albin Nielsen, Thomas A Nielsen, Peter W Reeh

Open access · hybridAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD.The Journal of investigative dermatology · 2025
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 6 countries.

Lars Arendt-NielsenCenter for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, School of Medicine, Aalborg University, Aalborg, Denmark.ORCID 0000-0003-0892-1579
Earl CarstensNeurobiology, Physiology and Behavior, University of California, Davis.
Gordon ProctorCentre for Host-Microbiome Interactions, Professor of Salivary Biology, King´s College London, UK.ORCID 0000-0002-5684-841X
Yves BoucherLaboratory of Orofacial Neurobiology, Paris Diderot University, Paris, France.
Pere ClavéCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Hospital de Mataró, Universitat Autònoma de Barcelona, Mataró, Barcelona, Spain.
Kent Albin NielsenNicotine Science Center, Fertin Pharma A/S, Vejle, Denmark.
Thomas A NielsenMech-Sense & Centre for Pancreatic Diseases, Department of Gastroenterology & Hepatology, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.
Peter W ReehInstitute Physiology and Pathophysiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Aalborg University Hospital · DKDélégation Paris 7 · FRFertin Pharma (Denmark) · DKFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKing's College London · GBUniversitat Autònoma de Barcelona · ESUniversity of California, Davis · US

Funding

Role of NK-1 receptors in descending modulation and ascending transmission of itchR01AR076434 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARSTENS, EARL E · 2020 to 2024
$1.7M
NIAMS NIH HHS R01 AR076434
6 · The paper itself

Abstract

Tobacco smoking-related diseases are estimated to kill more than 8 million people/year and most smokers are willing to stop smoking. The pharmacological approach to aid smoking cessation comprises nicotine replacement therapy (NRT) and inhibitors of the nicotinic acetylcholine receptor, which is activated by nicotine. Common side effects of oral NRT products include hiccoughs, gastrointestinal disturbances and, most notably, irritation, burning and pain in the mouth and throat, which are the most common reasons for premature discontinuation of NRT and termination of cessation efforts. Attempts to reduce the unwanted sensory side effects are warranted, and research discovering the most optimal masking procedures is urgently needed. This requires a firm mechanistic understanding of the neurobiology behind the activation of sensory nerves and their receptors by nicotine. The sensory nerves in the oral cavity and throat express the so-called transient receptor potential (TRP) channels, which are responsible for mediating the nicotine-evoked irritation, burning and pain sensations. Targeting the TRP channels is one way to modulate the unwanted sensory side effects. A variety of natural (Generally Recognized As Safe [GRAS]) compounds interact with the TRP channels, thus making them interesting candidates as safe additives to oral NRT products. The present narrative review will discuss (1) current evidence on how nicotine contributes to irritation, burning and pain in the oral cavity and throat, and (2) options to modulate these unwanted side-effects with the purpose of increasing adherence to NRT. Nicotine provokes irritation, burning and pain in the oral cavity and throat. Managing these side effects will ensure better compliance to oral NRT products and hence increase the success of smoking cessation. A specific class of sensory receptors (TRP channels) are involved in mediating nicotine's sensory side effects, making them to potential treatment targets. Many natural (Generally Recognized As Safe [GRAS]) compounds are potentially beneficial modulators of TRP channels.

Indexed as

Smoking CessationTransient Receptor Potential ChannelsAnimalsHumansMouthNicotineNicotinic AgonistsPainPharynxTobacco Use Cessation DevicesNicotineNicotinic AgonistsTransient Receptor Potential Channels

Identifiers

PMID35199839
PMCPMC9653082
OpenAlexW4213435942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.